Literature DB >> 21890086

Predictors of response to cardiac resynchronization therapy in patients with a non-left bundle branch block morphology.

John Rickard1, Mohamed Bassiouny, Edmond M Cronin, David O Martin, Niraj Varma, Mark J Niebauer, Patrick J Tchou, W H Wilson Tang, Bruce L Wilkoff.   

Abstract

Patients with non-left bundle branch block (LBBB) morphologies are thought to derive less benefit from cardiac resynchronization therapy (CRT) than those with LBBB. However, some patients do exhibit improvement. The characteristics associated with a response to CRT in patients with non-LBBB morphologies are unknown. Clinical, electrocardiographic, and echocardiographic data were collected from 850 consecutive patients presenting for a new CRT device. For inclusion, all patients had a left ventricular ejection fraction of ≤35%, a QRS duration of ≥120 ms, and baseline and follow-up echocardiograms available. Patients with a paced rhythm or LBBB were excluded. The response was defined as an absolute decrease in left ventricular end-systolic volume of ≥10% from baseline. Multivariate models were constructed to identify variables significantly associated with the response and long-term outcomes. A total of 99 patients met the inclusion criteria. Of these 99 patients, 22 had right bundle branch block and 77 had nonspecific intraventricular conduction delay; 52.5% met the criteria for response. On multivariate analysis, the QRS duration was the only variable significantly associated with the response (odds ratio per 10-ms increase 1.23, 95% confidence interval 1.01 to 1.52, p = 0.048). During a mean follow-up of 5.4 ± 0.9 years, 65 patients died or underwent heart transplant or left ventricular assist device placement. On multivariate analysis, the QRS duration was inversely associated with poor long-term outcomes (hazard ratio per 10-ms increase 0.79, 95% confidence interval 0.66 to 0.94, p = 0.005). In patients with advanced heart failure and non-LBBB morphologies, a wider baseline QRS duration is an important determinant of enhanced reverse ventricular remodeling and improved long-term outcomes after CRT.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21890086     DOI: 10.1016/j.amjcard.2011.07.017

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Periprocedural management of cardiac resynchronization therapy.

Authors:  John Rickard; Niraj Varma
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-04

Review 2.  Optimizing Cardiac Resynchronization Therapy: an Update on New Insights and Advancements.

Authors:  Adam Grimaldi; Eiran Z Gorodeski; John Rickard
Journal:  Curr Heart Fail Rep       Date:  2018-06

Review 3.  Focused Update of 2016 Korean Society of Heart Failure Guidelines for the Management of Chronic Heart Failure.

Authors:  Kyung-Jin Kim; Hyun-Jai Cho; Min-Seok Kim; Jeehoon Kang; Kyung-Hee Kim; Darea Kim; Suk Min Seo; Jeong Hoon Yang; Myung-Jin Cha; Jong Il Choi; Dong-Ju Choi
Journal:  Int J Heart Fail       Date:  2019-10-08

Review 4.  An Overview of Current Cardiac Resynchronization Therapy.

Authors:  Chien-Ming Cheng; Jin-Long Huang; Tsu-Juey Wu; Yu-Cheng Hsieh; Kuo-Yang Wang; Shih-Ann Chen
Journal:  Acta Cardiol Sin       Date:  2013-11       Impact factor: 2.672

5.  Electrocardiographic Parameters as Predictors of Response to Cardiac Resynchronization Therapy.

Authors:  Lidija Poposka; Vladimir Boskov; Dejan Risteski; Jane Taleski; Filip Janusevski; Elizabeta Srbinovska; Ljubica Georgievska-Ismail
Journal:  Open Access Maced J Med Sci       Date:  2018-02-09

6.  Role of Strauss ECG criteria as predictor of response in patients undergoing cardiac resynchronization therapy.

Authors:  Khaled Ashraf Shoman; Hayam Mohammed Eldamanhory; Emad Effat Fakhry; Haitham Abdelfatah Badran
Journal:  Egypt Heart J       Date:  2022-09-30

7.  Preventing phrenic nerve stimulation by a patch insulation in an intact swine heart model.

Authors:  Jin-Long Huang; Yenn-Jiang Lin; Yi-Wen Hung; Yu-Cheng Hsieh; Chien-Ming Cheng; Kuo-Yang Wang
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.